The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward - PubMed (original) (raw)

The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward

Pere P Simarro et al. PLoS Negl Trop Dis. 2011.

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1

Figure 1. Percentage of second stage T. b. gambiense patients treated according to drug used.

Eflornithine versus melarsoprol (2003–2009).

Figure 2

Figure 2. Institutional rate use of eflornithine.

National Sleeping Sickness Control Programmes versus nongovernmental organizations (2003–2009).

Figure 3

Figure 3. Evolution of reported cases of both forms of human African trypanosomiasis (1998–2009).

Figure 4

Figure 4. Classification of human African trypanosomiasis-endemic countries according to cases reported in 2009.

Similar articles

Cited by

References

    1. Magnus E, Vervoot T, Van Neirvenne N. A card agglutination test with stained trypanosomes (CATT) for the serological diagnosis of T. b. gambiense trypanosomiasis. Ann Soc Belg Med Trop. 1978;58:169–176. - PubMed
    1. Smith DH, Pepin J, Stich AH. Human African trypanosomiasis: an emerging public health crisis. Br Med Bull. 1998;54:341–355. - PubMed
    1. Stich A, Barrett MP, Krishna S. Waking up to sleeping sickness. Trends Parasitol. 2003;19:195–197. - PubMed
    1. Sjoerdsma A, Schechter PJ. Eflornithine for African sleeping sickness. Lancet. 1999;354:254. - PubMed
    1. World Health Organization. Report of a WHO Expert Committee. WHO technical report series 881. Geneva: World Health Organization; 1998. Control and surveillance of African trypanosomiasis. - PubMed

MeSH terms

LinkOut - more resources